Cannabis and pharmaceutical research
Marijuana is a promising medicine in the pharmaceutical industry. Marijuana has many medical and therapeutic benefits. Research into the compounds of cannabis has proven to be profitable for the medical industry. The legalization of medical marijuana has spread to many countries, and it is expected to continue. The FDAhas approved the only cannabis-derived medicine last year called, Epidiolex.
The vice-president of Canada medical, Amanda Daley, said that the opportunities in pharmaceuticals for cannabis are vast and never-ending. Daley also stated that the Canopy Corporation has been able to research the interaction between cannabis use, patients, and medical practitioners. Medical cannabis is usually consumed to relieve pain and improve sleep. Canada is one of the first countries in the world to legalize medical cannabis nationwide.
Cannabis prescriptions becoming a trend
Many doctors have started to prescribe cannabis regularly. It is estimated that approximately 20% of the Canadian doctors are prescribing cannabis drugs, and some medical practitioners also refer patients with various illnesses to other doctors who can assist with medical cannabis.
The medical cannabis industry had an increase in the number of medical cannabis patients in Canada.
There is much research to be done on the compounds of cannabis. Canopy Growth Corporation has made progress thus far in providing the public with information on medical cannabis. It has also tried to conduct its own research on cannabis.
Due to a lack of research into the properties of the marijuana plant, some medical practitioners are hesitant to prescribe cannabis medicine. However, some doctors take the initiative to provide their patients with advice on consuming medical cannabis.
Accessibility to medical cannabis
Generally, a patient should get approval from his or her medical doctor to access medical cannabis. In some instances, a patient may get a license to purchase cannabis through pharmacies and local dispensaries.
Big Pharma and pharmaceuticals
Due to the medical benefits of cannabis Big Pharma, the global pharmaceutical industry has shown interest in medical cannabis. Big Pharma is a group of pharmaceutical companies. The medical cannabis industry is estimated to reach over 5 billion dollars this year, which is a lot of money generated from this industry, and Big Pharma wants to secure some of the profits from medical cannabis sales now that there is a growing number of medical cannabis consumers.
Some of Canada’s patent holders have influence in the pharmaceutical industry. Seven of these patent holders are huge pharmaceutical companies. Since medical cannabis is legal in Canada, some investors have been interested in making investments in medical cannabis. However, the United States, the laws, and regulations are a little difficult to navigate. That is because cannabis is still illegal under federal law. Therefore, investors are not so eager to invest in the cannabis industry.
Patent holders are also inclusive of universities and health services. Despite the successes of partnerships in this area, there have been some key setbacks, such as the stigma attached to cannabis use. Many people are still not educated on the effects of cannabis use. They are unaware that THC products have different effects from CBD products. THC products can cause you to get ‘high’ because of the psychoactive effect of THC, where CBD products are medicinally based.
Additional cannabis research needed
Research into the medical benefits of cannabis is still limited to clinical trials in animals and laboratories. There isn’t much study involving humans except the compilation of anecdotal evidence.
The future of medical cannabis
Medical cannabis continues to generate wealth for Canada. As time progresses, medical cannabis will grow into a powerful pharmaceutical industry.